Study of Giant Viruses of Amoebas Infections in Children Suffering From Gastroenteritis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02855463

Enrollment

1000

Registered

2016-08-04

Start date

2011-07-31

Completion date

2016-12-31

Last updated

2016-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteritis

Keywords

Giant virus, Amoeba

Brief summary

The discovery in 2003 by isolation of amoebas Mimivirus, the world's largest virus at the Research Unit on Tropical and Emerging Diseases in Marseille revealed fascinating information about the definition and evolution of viruses. Its genome encodes about 1,000 proteins. Three other viruses were then isolated from amoebas in this unit:Two other giant viruses, Mamavirus Marseillevirus then, and the first virus a virus, named virophage, which led to highlight the role of amoeba (Acanthamoeba spp. ) such as spawning giant viruses and compounds of bacterial origin or cellular proteins This project focuses on the detection and analysis of new viral agents (viruses and virophages giant amoeba environmental) and their involvement in human pathology. The objectives of this study are observational: detect and document the presence of giant viruses and virophages of amoebae in the faeces of children presenting to the pediatric emergency reception service of the North Hospital in AP -HM with or without clinical evidence of gastroenteritis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 15 Years

Healthy volunteers

Inclusion criteria

* Patient admitted in the Pediatric Emergency Service of Northern Hospital, Marseille, France * Patient aged ≤ 15.3 years, male or female; * Patient for whom a microbiological exam should be performed during the clinical management, with or without a clinical diagnosis of gastroenteritis (ie including diarrhea which will be defined by the issuance of at least three molded or watery stools per day for more than 24 hours) at the time of the collection of stool; * Patient for whom informed consent was read, understood, signed by a parent or legal representative.

Exclusion criteria

* Patient aged \> 15.3 years; * Patient for whom informed consent is not signed by a parent or legal representative.

Design outcomes

Primary

Measure	Time frame
Number of children carriers in their digestive tract of giant viruses (and their virophages) associated with amoebae	1 day

Countries

France

Contacts

Primary ContactUrielle DESALBRES

urielle.desalbres@ap-hm.fr04 91 38 20 61

Outcome results